{"id":"https://openalex.org/W7204684413","doi":"https://doi.org/10.1016/s2152-2650(26)01647-2","title":"ALL-221: Healthcare Resource Use and Economic Burden of B-Cell Acute Lymphoblastic Leukemia for Patients in the United States","display_name":"ALL-221: Healthcare Resource Use and Economic Burden of B-Cell Acute Lymphoblastic Leukemia for Patients in the United States","publication_year":2026,"publication_date":"2026-08-01","ids":{"openalex":"https://openalex.org/W7204684413","doi":"https://doi.org/10.1016/s2152-2650(26)01647-2"},"language":"en","primary_location":{"id":"doi:10.1016/s2152-2650(26)01647-2","doi":"https://doi.org/10.1016/s2152-2650(26)01647-2","is_oa":false,"landing_page_url":"https://doi.org/10.1016/s2152-2650(26)01647-2","pdf_url":null,"source":{"id":"https://openalex.org/S186546955","display_name":"Clinical Lymphoma Myeloma & Leukemia","issn_l":"2152-2650","issn":["2152-2650","2152-2669"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","dongbi-d","doyens","jufo-1","ki-jl-1","medline","norway-1","poland-70","russia-white-list-3","vabb-shw"],"host_organization":"https://openalex.org/P4310320990","host_organization_name":"Elsevier BV","host_organization_lineage":["https://openalex.org/P4310320990"],"host_organization_lineage_names":["Elsevier BV"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Clinical Lymphoma Myeloma and Leukemia","raw_type":"journal-article"},"volume":null,"type":"conference-abstract","is_traditional":false,"indexed_in":["crossref"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5050068696","display_name":"Neil David Palmisiano","orcid":"https://orcid.org/0000-0003-1524-8108","observed_orcids":["https://orcid.org/0000-0003-1524-8108"]},"institutions":[{"id":"https://openalex.org/I102322142","display_name":"Rutgers, The State University of New Jersey","ror":"https://ror.org/05vt9qd57","country_code":"US","type":"education","lineage":["https://openalex.org/I102322142"]},{"id":"https://openalex.org/I4390039325","display_name":"Rutgers Cancer Institute","ror":"https://ror.org/0060x3y55","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I102322142","https://openalex.org/I4390039302","https://openalex.org/I4390039325"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Neil D Palmisiano","raw_affiliation_strings":["Rutgers Cancer Institute, Rutgers University, New Brunswick, NJ, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Rutgers Cancer Institute, Rutgers University, New Brunswick, NJ, USA","institution_ids":["https://openalex.org/I102322142","https://openalex.org/I4390039325"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5065537882","display_name":"Yazan K. Barqawi","orcid":"https://orcid.org/0000-0002-3045-6813","observed_orcids":["https://orcid.org/0000-0002-3045-6813"]},"institutions":[{"id":"https://openalex.org/I4210150756","display_name":"AstraZeneca (United States)","ror":"https://ror.org/043cec594","country_code":"US","type":"company","lineage":["https://openalex.org/I105036370","https://openalex.org/I4210150756"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Yazan K Barqawi","raw_affiliation_strings":["AstraZeneca, Gaithersburg, MD, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"AstraZeneca, Gaithersburg, MD, USA","institution_ids":["https://openalex.org/I4210150756"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5148722243","display_name":"Julia Ma","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210149652","display_name":"AstraZeneca (Canada)","ror":"https://ror.org/04n8fbz89","country_code":"CA","type":"company","lineage":["https://openalex.org/I105036370","https://openalex.org/I4210149652"]}],"countries":["CA"],"is_corresponding":false,"raw_author_name":"Julia Ma","raw_affiliation_strings":["AstraZeneca, Mississauga, Canada"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"AstraZeneca, Mississauga, Canada","institution_ids":["https://openalex.org/I4210149652"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5062477688","display_name":"Debbie Adkins","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I105036370","display_name":"AstraZeneca (United Kingdom)","ror":"https://ror.org/04r9x1a08","country_code":"GB","type":"company","lineage":["https://openalex.org/I105036370"]}],"countries":["GB"],"is_corresponding":false,"raw_author_name":"Debbie Adkins","raw_affiliation_strings":["AstraZeneca, Macclesfield, United Kingdom"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"AstraZeneca, Macclesfield, United Kingdom","institution_ids":["https://openalex.org/I105036370"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5148671599","display_name":"Jesica M Levingston Mac Leod","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I105036370","display_name":"AstraZeneca (United Kingdom)","ror":"https://ror.org/04r9x1a08","country_code":"GB","type":"company","lineage":["https://openalex.org/I105036370"]}],"countries":["GB"],"is_corresponding":false,"raw_author_name":"Jesica M Levingston Mac Leod","raw_affiliation_strings":["AstraZeneca, London, United Kingdom"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"AstraZeneca, London, United Kingdom","institution_ids":["https://openalex.org/I105036370"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5148687905","display_name":"Jenny Lam","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210150756","display_name":"AstraZeneca (United States)","ror":"https://ror.org/043cec594","country_code":"US","type":"company","lineage":["https://openalex.org/I105036370","https://openalex.org/I4210150756"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Jenny Lam","raw_affiliation_strings":["AstraZeneca, Gaithersburg, MD, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"AstraZeneca, Gaithersburg, MD, USA","institution_ids":["https://openalex.org/I4210150756"]}]}],"institutions":[],"countries_distinct_count":3,"institutions_distinct_count":5,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":{"value":3890,"currency":"USD","value_usd":3890},"apc_paid":null,"fwci":null,"has_fulltext":false,"cited_by_count":0,"citation_normalized_percentile":null,"cited_by_percentile_year":null,"biblio":{"volume":"26","issue":null,"first_page":"S386","last_page":"S387"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T12708","display_name":"Economic and Financial Impacts of Cancer","score":0.6234999895095825,"subfield":{"id":"https://openalex.org/subfields/2002","display_name":"Economics and Econometrics"},"field":{"id":"https://openalex.org/fields/20","display_name":"Economics, Econometrics and Finance"},"domain":{"id":"https://openalex.org/domains/2","display_name":"Social Sciences"}},"topics":[{"id":"https://openalex.org/T12708","display_name":"Economic and Financial Impacts of Cancer","score":0.6234999895095825,"subfield":{"id":"https://openalex.org/subfields/2002","display_name":"Economics and Econometrics"},"field":{"id":"https://openalex.org/fields/20","display_name":"Economics, Econometrics and Finance"},"domain":{"id":"https://openalex.org/domains/2","display_name":"Social Sciences"}},{"id":"https://openalex.org/T10950","display_name":"Acute Lymphoblastic Leukemia research","score":0.3637999892234802,"subfield":{"id":"https://openalex.org/subfields/2720","display_name":"Hematology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10804","display_name":"Health Systems, Economic Evaluations, Quality of Life","score":0.0032999999821186066,"subfield":{"id":"https://openalex.org/subfields/2002","display_name":"Economics and Econometrics"},"field":{"id":"https://openalex.org/fields/20","display_name":"Economics, Econometrics and Finance"},"domain":{"id":"https://openalex.org/domains/2","display_name":"Social Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/b-cell-acute-lymphoblastic-leukemia","display_name":"B-cell acute lymphoblastic leukemia","score":0.9729999899864197},{"id":"https://openalex.org/keywords/healthcare-resource-utilization","display_name":"healthcare resource utilization","score":0.8209999799728394},{"id":"https://openalex.org/keywords/economic-burden","display_name":"economic burden","score":0.9639999866485596},{"id":"https://openalex.org/keywords/blinatumomab","display_name":"blinatumomab","score":0.765999972820282},{"id":"https://openalex.org/keywords/car-t-cell-therapy","display_name":"CAR T-cell therapy","score":0.8989999890327454},{"id":"https://openalex.org/keywords/inotuzumab","display_name":"inotuzumab","score":0.7910000085830688},{"id":"https://openalex.org/keywords/tyrosine-kinase-inhibitors","display_name":"tyrosine kinase inhibitors","score":0.9319999814033508},{"id":"https://openalex.org/keywords/rituximab","display_name":"rituximab","score":0.9020000100135803},{"id":"https://openalex.org/keywords/first-line-treatment","display_name":"first-line therapy","score":0.5220000147819519},{"id":"https://openalex.org/keywords/treatment-costs","display_name":"treatment costs","score":0.4050000011920929},{"id":"https://openalex.org/keywords/payer-perspective","display_name":"payer perspective","score":0.5149999856948853},{"id":"https://openalex.org/keywords/hospitalization","display_name":"hospitalization","score":0.5849999785423279},{"id":"https://openalex.org/keywords/outpatient-visits","display_name":"outpatient visits","score":0.9190000295639038},{"id":"https://openalex.org/keywords/drug-costs","display_name":"drug costs","score":0.5799999833106995},{"id":"https://openalex.org/keywords/united-states-adults","display_name":"United States adults","score":0.4860000014305115},{"id":"https://openalex.org/keywords/health-insurance","display_name":"health insurance","score":0.36899998784065247}],"concepts":[{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.9767000079154968},{"id":"https://openalex.org/C3017409249","wikidata":"https://www.wikidata.org/wiki/Q23582796","display_name":"Resource use","level":2,"score":0.7840999960899353},{"id":"https://openalex.org/C2909962599","wikidata":"https://www.wikidata.org/wiki/Q180664","display_name":"Lymphoblastic Leukemia","level":3,"score":0.5950000286102295},{"id":"https://openalex.org/C177713679","wikidata":"https://www.wikidata.org/wiki/Q679690","display_name":"Intensive care medicine","level":1,"score":0.5684999823570251},{"id":"https://openalex.org/C160735492","wikidata":"https://www.wikidata.org/wiki/Q31207","display_name":"Health care","level":2,"score":0.46560001373291016},{"id":"https://openalex.org/C545542383","wikidata":"https://www.wikidata.org/wiki/Q2751242","display_name":"Medical emergency","level":1,"score":0.3885999917984009},{"id":"https://openalex.org/C194828623","wikidata":"https://www.wikidata.org/wiki/Q2861470","display_name":"Emergency medicine","level":1,"score":0.37869998812675476},{"id":"https://openalex.org/C2779473830","wikidata":"https://www.wikidata.org/wiki/Q1540899","display_name":"MEDLINE","level":2,"score":0.3463999927043915},{"id":"https://openalex.org/C206345919","wikidata":"https://www.wikidata.org/wiki/Q20380951","display_name":"Resource (disambiguation)","level":2,"score":0.31529998779296875},{"id":"https://openalex.org/C2781107101","wikidata":"https://www.wikidata.org/wiki/Q180664","display_name":"Acute lymphocytic leukemia","level":4,"score":0.2743000090122223},{"id":"https://openalex.org/C2989236134","wikidata":"https://www.wikidata.org/wiki/Q31207","display_name":"Patient care","level":2,"score":0.2653000056743622},{"id":"https://openalex.org/C2988170871","wikidata":"https://www.wikidata.org/wiki/Q11000047","display_name":"Healthcare system","level":3,"score":0.26260000467300415}],"mesh":[],"locations_count":1,"locations":[{"id":"doi:10.1016/s2152-2650(26)01647-2","doi":"https://doi.org/10.1016/s2152-2650(26)01647-2","is_oa":false,"landing_page_url":"https://doi.org/10.1016/s2152-2650(26)01647-2","pdf_url":null,"source":{"id":"https://openalex.org/S186546955","display_name":"Clinical Lymphoma Myeloma & Leukemia","issn_l":"2152-2650","issn":["2152-2650","2152-2669"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","dongbi-d","doyens","jufo-1","ki-jl-1","medline","norway-1","poland-70","russia-white-list-3","vabb-shw"],"host_organization":"https://openalex.org/P4310320990","host_organization_name":"Elsevier BV","host_organization_lineage":["https://openalex.org/P4310320990"],"host_organization_lineage_names":["Elsevier BV"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Clinical Lymphoma Myeloma and Leukemia","raw_type":"journal-article"}],"best_oa_location":null,"sustainable_development_goals":[{"score":0.98580002784729,"display_name":"Good health and well-being","id":"https://metadata.un.org/sdg/3"}],"study_designs":[],"awards":[],"funders":[],"has_content":{"grobid_xml":false,"pdf":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W4388783856","https://openalex.org/W2954357255","https://openalex.org/W4390841107","https://openalex.org/W3136627192","https://openalex.org/W4310107914","https://openalex.org/W4417019797","https://openalex.org/W2721997803","https://openalex.org/W4283379664","https://openalex.org/W4312007581","https://openalex.org/W4297339166"],"abstract_inverted_index":null,"counts_by_year":[],"updated_date":"2026-09-22T06:50:58.402377","created_date":"2026-08-31T00:00:00"}